Pure Collaborations

From the FDA to multi-national corporations, Pure is engineered for collaboration.

Contract Epitope Discovery

Partnering to fight Hepatitis and Leukemia.

A major pharmaceutical company and Pure Protein have a research agreement under negotiation to use Pure’s proprietary epitope discovery technology to identify and define epitopes unique to the HBV particle and to leukemia-associated antigens in AML. The goal of the project is disease control through targeting the HBV particles or leukemic cell epitopes for destruction by the patient’s own immune system.